Crikey - some of the analyst reports on BIT are looking quite bleak.
Biotron Faces Trial Challenges and Leadership Changes | Markets Insider
Biotron Faces Trial Challenges and Leadership Changes
Biotron Limited faced challenges in its recent clinical trials, as the primary endpoints were not met, leading to frustration among shareholders. Despite these setbacks, the company continues to pursue commercialisation opportunities and has engaged a US-based consulting group to explore potential partnerships. The AGM also marked the resignation of two long-standing directors, highlighting a period of transition for the company.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.654M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $210 | 104.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 38848316 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 18281126 | 25 |
View Market Depth
| Last trade - 12.28pm 27/06/2025 (20 minute delay) ? |
| BIT (ASX) Chart |